Disease Review Sample Clauses

Disease Review. The central and peripheral nervous systems control storage of urine in the bladder and also control voiding to eliminate the urine. During the bladder cycle storage phase in healthy adults, inhibitory neuronal signals prevent detrusor muscle contraction, while excitatory inputs keep the urethral sphincters closed; so that urine in the bladder is stored until voluntary voiding is initiated. At the time of voluntary voiding there is a reverse of this process with a coordinated contraction of the detrusor muscle and relaxation of the urethral sphincters to enable controlled voluntary voiding. Thus, in the normal situation the detrusor muscle only contracts during the bladder cycle voiding phase and remains relaxed during the storage phase. However, neurological disruption of the lower urinary tract may lead to disinhibition of the detrusor muscle and the occurrence of involuntary detrusor contractions (IDCs) during the storage phase, also known as detrusor overactivity. Urodynamic testing is required to identify IDCs during the bladder cycle storage phase, which typically appear as phasic rises in bladder pressure during filling cystometry [1]. Many diseases and events affecting the nervous system controlling the lower urinary tract can result in neurogenic detrusor overactivity (NDO); including multiple sclerosis (MS), spinal cord iujury (SCI), Parkiusou's disease, stroke and brain tumours. Unlike supraspinal lesions, MS and SCI both affect the spinal cord and share common characteristics. Since they are also relatively prevalent and often result in NDO, they have been frequently assessed together in clinical studies evaluating treatments for NDO. Neurogenic bladder dysfunction affects up to 80% of individuals with MS and SCI, with the majority of these individuals having NDO and urinary incontinence (UI) [2]. The principal NDO-related symptom is UI, which is an involuntary loss of urine due to IDCs during the bladder storage phase. Since patients with NDO can experience frequent UI episodes, along with other symptoms, such as increased urinary frequency, their quality of life (QoL) may be significantly impaired [2]. Patients with NDO, particularly those with suprasacral lesions, may also have voiding dysfunction due to the disruption of the innervation of the urethral sphincter mechanism. Such patients require regular clean intermittent catheterisation (CIC) to effectively empty the bladder. In addition, the regular emptying of the bladder using CIC may als...
Sample 1
AutoNDA by SimpleDocs

Related to Disease Review

  • Midterm Review The Recipient shall:

  • Exclusion Review Notwithstanding any provision of Title 42 of the United States Code or Title 42 of the Code of Federal Regulations, the only issues in a proceeding for exclusion based on a material breach of this CIA shall be:

  • Log Reviews All systems processing and/or storing PHI COUNTY discloses to 11 CONTRACTOR or CONTRACTOR creates, receives, maintains, or transmits on behalf of COUNTY 12 must have a routine procedure in place to review system logs for unauthorized access.

  • Mid-Term Review The Borrower shall:

  • Validation Review In the event OIG has reason to believe that: (a) Good Shepherd’s Claims Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Good Shepherd shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good Shepherd’s final Annual Report shall be initiated no later than one year after Good Shepherd’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd may request a meeting with OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or to correct the inaccuracy of the Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

  • Utilization Review We review health services to determine whether the services are or were Medically Necessary or experimental or investigational ("Medically Necessary"). This process is called Utilization Review. Utilization Review includes all review activities, whether they take place prior to the service being performed (Preauthorization); when the service is being performed (concurrent); or after the service is performed (retrospective). If You have any questions about the Utilization Review process, please call the number on Your ID card. The toll-free telephone number is available at least 40 hours a week with an after-hours answering machine. All determinations that services are not Medically Necessary will be made by: 1) licensed Physicians; or 2) licensed, certified, registered or credentialed health care professionals who are in the same profession and same or similar specialty as the Provider who typically manages Your medical condition or disease or provides the health care service under review. We do not compensate or provide financial incentives to Our employees or reviewers for determining that services are not Medically Necessary. We have developed guidelines and protocols to assist Us in this process. Specific guidelines and protocols are available for Your review upon request. For more information, call the number on Your ID card or visit Our website at xxx.xxxxxxx.xxx.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Program Review The Contracting Officer or other authorized government representative may hold semi- annual program review meetings. Such meetings will be held via telecom or video teleconferencing. However, the Government reserves the right to request a meeting in person. The meetings will include all BPA holders, representatives from prospective customer agencies, a combination of current and prospective customer agencies, or individual BPA holders. Some Federal Government Agencies and any approved State, Local and Tribal agencies may establish a central program management function. Such users may require their primary suppliers to participate in agency program review meetings on a periodic basis, at no additional cost to the Government.

  • Additional RO Review Criteria (1) In addition to the requirements in Subparagraph 34A, the RO must:

  • Joint Review JADRC may, at the request of either party, review issues arising from the application of this Article.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!